Corpus Intelligence IC Memo — HIGHLAND HOSPITAL 2026-04-26 09:08 UTC
IC Memo — HIGHLAND HOSPITAL
Investment Committee Memorandum | NY | 261 beds | Grade C | EBITDA uplift $33.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HIGHLAND HOSPITAL

CCN 330164 | MONROE, NY | 261 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HIGHLAND HOSPITAL is a 261-bed suburban community hospital in MONROE, NY with $456.8M in net patient revenue and a -11.0% operating margin. The hospital serves a payer mix of 19.7% Medicare, 1.8% Medicaid, and 78.6% commercial.

Thesis: Undervalued. Our ML models identify $33.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -11.0% to -3.6% (+736bps).

Net Revenue HCRIS$456.8M
Current EBITDA COMPUTED$-50.1M
Operating Margin COMPUTED-11.0%
Occupancy HCRIS96.3%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS36.3%
Distress Probability ML37.2%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
97
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -11.0% places it above the state median. Among 97 size-comparable peers (130-522 beds), the median margin is -18.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (130-522), prioritizing same-state peers. 97 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HIGHLAND HOSPITAL (Target)NY261$456.8M-11.0%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
LENOX HILL HOSPITALNY415$1.32B-35.1%
STATEN ISLAND UNIVERSITY HOSPINY515$1.23B-34.6%
JACOBI MEDICAL CENTERNY440$1.14B-16.8%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
ROCHESTER GENERAL HOSPITALNY470$1.05B-27.9%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%
NEWYORK-PRESBYTERIAN/QUEENSNY476$890.1M-50.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $33.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$9.6M+210bp18mo
Cost to Collect4.5%2.5%$9.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$9.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$5.6M+122bp9mo
Clean Claim Rate88.0%96.0%$292K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$9.6M
Cost to Collect
$9.1M
Denial Rate Reduction
$9.0M
A/R Days Reduction
$5.6M
Clean Claim Rate
$292K
Total EBITDA Uplift$33.6M
Current EBITDA$-50.1M
+ RCM Uplift+$33.6M
Pro Forma EBITDA$-16.5M
Current Margin-11.0%
Pro Forma Margin-3.6%
WC Released (1x)$17.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-77.1M$5.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-77.1M$-18.8M0.00x-100.0%
Bull Case9.0x11.0x$-69.4M$67.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-69.4M$52.8M0.00x-100.0%
Bear Case11.0x10.0x$-84.8M$-137.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-84.8M$-178.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 97 hospitals with 130-522 beds
  • Same-state prioritization (n=98)
  • Comp margins: P25=-28.6% / P50=-18.2% / P75=-9.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.